Elisabet Björklund

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. ncbi Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment
    Elisabet Björklund
    Department of Pathology and Cytology, Karolinska University Hospital, Solna, Karolinska Institute, Stockholm SE 171 76, Sweden
    J Pediatr Hematol Oncol 31:406-15. 2009
  2. ncbi CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients
    Elisabet Björklund
    Department of Pathology, Karolinska University Hospital, Solna and Karolinska Institute, 171 76, Stockholm, Sweden
    Int J Hematol 90:292-302. 2009
  3. ncbi Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia
    Asa Rangert Derolf
    Department of Medicine, Division of Hematology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden
    Leuk Lymphoma 49:1279-91. 2008
  4. ncbi Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
    Miroslav Djokic
    1Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 94:1016-9. 2009
  5. ncbi Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
    Leonie Saft
    Department of Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Stockholm, Sweden
    Leuk Res 37:266-73. 2013

Detail Information

Publications5

  1. ncbi Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment
    Elisabet Björklund
    Department of Pathology and Cytology, Karolinska University Hospital, Solna, Karolinska Institute, Stockholm SE 171 76, Sweden
    J Pediatr Hematol Oncol 31:406-15. 2009
    ..The concordance was higher in precursor B as compared with T-cell ALL. We conclude that after standardization, flow cytometry MRD detection can be reliably applied in international, multicenter treatment protocols...
  2. ncbi CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients
    Elisabet Björklund
    Department of Pathology, Karolinska University Hospital, Solna and Karolinska Institute, 171 76, Stockholm, Sweden
    Int J Hematol 90:292-302. 2009
    ..The 8-color technique showed promising results in efficient detection of different CD34+ subpopulations of HSC-B and in MRD quantification. Monitoring of MRD should become a part of quality control of HSC-B collections...
  3. ncbi Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia
    Asa Rangert Derolf
    Department of Medicine, Division of Hematology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm, Sweden
    Leuk Lymphoma 49:1279-91. 2008
    ..004, cytogenetics p = 0.011, immunophenotype pattern p = 0.024, CD15 p = 0.031). Age (p = 0.001) and immunophenotypic classifications (p = 0.015) were significant for disease-free survival in patients who achieved complete remission...
  4. ncbi Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
    Miroslav Djokic
    1Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 94:1016-9. 2009
    ..Moreover, aberrant CD123 expression in ALL is a good marker for monitoring of minimal residual disease...
  5. ncbi Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
    Leonie Saft
    Department of Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Stockholm, Sweden
    Leuk Res 37:266-73. 2013
    ..DC levels were markedly reduced in all subtypes of MDS. The clinical impact of this finding on therapy response and relapse after, e.g. allogeneic stem cell transplantation warrants further investigation...